Active — Not RecruitingNot Applicable

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

United States20 participantsStarted 2024-09-04

Plain-language summary

The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH). Low-resistance training is an evidence-based approach that may help patients improve their functional ability.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of PAH: idiopathic, heritable, associated with connective tissue disease, congenital heart disease, human immunodeficiency virus, drug- or toxin, or portopulmonary hypertension * On stable PAH therapy for 3 months Exclusion Criteria: * World Health Organization (WHO) functional class IV * Left ventricular ejection fraction \< 40% (via transthoracic echocardiogram (TTE) within one year of screening) * Moderate or severe concomitant lung disease: Chronic Obstructive Pulmonary Disease (COPD) or interstitial lung disease * Enrollment in a clinical trial * Recent hospitalization (within 4 weeks of screening) * Inability to perform the Short Physical Performance Battery or wheelchair bound

What they're measuring

Adverse Events

Timeframe: Between baseline and 12-week follow-up

Feasibility of Recruitment

Timeframe: Through study completion, an average of twice per year

Feasibility of Study

Timeframe: Through study completion, an average of twice per year

Short Performance Physical Battery (SPPB) and emPHasis-10 (E10) scores

Timeframe: Between baseline and 12-week follow-up

Patient/ Caregiver Exit Interview

Timeframe: Upon conclusion of the 12-week follow-up

Trial details

NCT IDNCT06543745

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

View on ClinicalTrials.gov More Pulmonary Arterial Hypertension trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Adverse Events

Timeframe: Between baseline and 12-week follow-up

Feasibility of Recruitment

Timeframe: Through study completion, an average of twice per year

Feasibility of Study

Timeframe: Through study completion, an average of twice per year

Short Performance Physical Battery (SPPB) and emPHasis-10 (E10) scores

Timeframe: Between baseline and 12-week follow-up

Patient/ Caregiver Exit Interview

Timeframe: Upon conclusion of the 12-week follow-up